PCSK9 antagonists
US12384855B2 · kind B2 · utility
0Cited by
10References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2019 |
| Grant date | Aug 12, 2025 |
| Priority date | — |
| Expiry date | Aug 19, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.